Macquarie Group
JSPR icon

Macquarie Group’s Jasper Therapeutics JSPR Stock Holding History

Macquarie Group’s Portfolio JSPR Stock Details JSPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-697
Closed -$20 – 2013
2024
Q1 		$20 Buy
+697
New +$12.4K ﹤0.01% 1691

Other funds holding JSPR

VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
QUSVM
Qiming U.S. Ventures Management Bellevue, Washington $55.6M AUM 98.09% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

Macquarie Group's JSPR Position: Q2 2024 in Review

Macquarie Group sold out of Jasper Therapeutics (JSPR) in Q2 2024, closing a stake of 697 shares — an estimated $20 sold.

Macquarie Group first reported a position in JSPR in Q1 2024 and held it in 1 quarter. The position peaked at $20 in Q1 2024. 69 funds tracked by Wall St. Rank hold JSPR as of Q2 2024.

  • Macquarie Group reported no remaining Jasper Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Macquarie Group sold 697 Jasper Therapeutics shares in Q2 2024, an estimated $20.
  • Macquarie Group first reported a position in Jasper Therapeutics in Q1 2024 and held it in 1 quarter.
  • Macquarie Group's Jasper Therapeutics position peaked at $20 in Q1 2024.
  • 69 funds tracked by Wall St. Rank held Jasper Therapeutics as of Q2 2024.

Based on Macquarie Group's 13F filing for Q2 2024, filed 9 Aug 2024.